Skip to main content

Xeris Biopharma Holdings, Inc.

XERS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001867096

In the last 90 days, Xeris Biopharma Holdings, Inc. insiders filed 0 open-market purchases and 10 sales; 242 institutions reported holding it in 13F filings for Q2 2026, worth $857.1M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Xeris Biopharma Holdings, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of XERS: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders9792−5
Shares53.9M49.5M−4.40M (−8.2%)
Value$71.6M$80.6M+$8.99M (+12.5%)

New holders (9)

Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to XERS in Q1 2023
InstitutionSharesValue% of portfolio
Rubric Capital Management LP426,267$694.8K0.03%
Gsa Capital Partners LLP316,025$515.0K0.05%
SG Americas Securities, LLC40,947$67.0K0.00%
Virtu Financial LLC31,498$51.0K0.01%
ProShare Advisors LLC25,011$40.8K0.00%
Van Hulzen Asset Management, LLC20,278$33.0K0.00%
Kavar Capital Partners Group, LLC17,000$27.7K0.01%
National Bank of Canada2,385$3.86K0.00%
Global Retirement Partners, LLC413$9540.00%

Sold out (14)

Institutions that held Xeris Biopharma Holdings, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.